Sabrina Serani

The FDA approval of Guardant Shield marks the second blood-based diagnostic test for colorectal cancer in those age 45 and older at average risk of the disease.

Andrew Brohl, MD, discussed findings from a study investigating a novel vaccine treatment for squamous cell and Merkel cell carcinomas.

A new dendritic cell vaccine has shown promising results in extending survival for pancreatic cancer patients by stimulating the immune system to fight tumor cells.

A study suggests a PIK3CA mutation and blood tests before and after treatment may predict response to alisertib in HR+/HER2–metastatic breast cancer.

Mridula George, MD, discussed a study investigating ctDNA monitoring during neoadjuvant therapy of breast cancer.

The CAR T-cell therapy UCART22 has been granted orphan drug designation and rare pediatric drug designation from the FDA for the treatment of acute lymphoblastic leukemia.

Findings from the phase 2 NeoPembrOV study supported the addition of pembrolizumab to neoadjuvant chemotherapy before surgery in high-grade serous ovarian cancer.

A phase 2 trial shows that THIO, a new investigational drug, combined with cemiplimab, may be an effective and well-tolerated treatment for patients with advanced non–small cell lung cancer who have exhausted other options.

Patients treated with hormone-modulating therapy for breast cancer had a reduced risk of developing Alzheimer disease or dementia compared with patients treated with other agents.

Bhavana Pothuri, MD, discussed the importance of testing and accessing treatment for patients with endometrial cancer.

Laura Huppert, MD, discussed a retrospective study exploring the sequential use of antibody-drug conjugates for the treatment of HER2-low metastatic breast cancer.

The FDA has accepted the resubmitted application of remestemcel-L, a potential first-of-its-kind treatment for pediatric patients following stem cell transplants.

The tyrosine kinase inhibitor entrectinib shows promising responses in patients with non–small cell lung cancer harboring a ROS1 mutation.

AIC100 now has a regenerative medicine advanced therapy designation from the FDA for the treatment of recurrent anaplastic thyroid cancer.

An analysis from the innovaTV 301 showed that tisotumab vedotin in the second- and third-line bettered overall survival vs investigator’s choice of chemotherapy in patients with cervical cancer.

Clinical development of ZW191 is planned to begin in the second half of 2024.

Erika Hamilton, MD, discussed findings from the phase 1b/2 ELECTRA study investigating a new oral combination therapy for patients with metastatic breast cancer.

Juneko Grilley-Olson, MD, discussed findings from a phase 2 study investigating the addition of immunotherapy to chemotherapy for the treatment of advanced angiosarcoma.

Robert Jotte, MD, PhD, discussed findings from the phase 3 KRYSTAL-12 study evaluating adagrasib vs docetaxel in previously treated KRAS G12C-mutated non–small cell lung cancer.

Patrick Boland, MD, discussed the practice-changing implications of the phase 3 ESOPEC study comparing FLOT vs CROSS regimens for the treatment of esophageal adenocarcinoma.

Patients who underwent hematopoietic cell transplantation had similar outcomes with matched vs mismatched unrelated donors when posttransplant cyclophosphamide was used.

Findings from the phase 3 ARANOTE trial demonstrated an improvement in radiographic progression-free survival with darolutamide vs placebo plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.

The FDA has accepted and granted priority review to tab-cel, a treatment for Epstein Barr virus-positive posttransplant lymphoproliferative disease.

A dendritic cell vaccine called DOC1021 shows early promise in treating pancreatic cancer and has received a fast track designation from the FDA.

A new study suggests a short course of immunotherapy before surgery may significantly improve outcomes in patients with high-risk melanoma.

A new immunotherapy combination of eftilagimod alpha and pembrolizumab shows promise in treating head and neck squamous cell carcinoma, even in patients with low PD-L1 expression.

Findings from the MARIPOSA trial showed that amivantamab plus lazertinib were superior to osimertinib for the treatment of EGFR-mutant non–small cell lung cancer.

The SKYSCRAPER-06 trial for the first-line treatment of non–small cell lung cancer was stopped because the combination of tiragolumab and atezolizumab did not improve survival compared with the control of pembrolizumab and chemotherapy.

Elizabeth Loggers, MD, PhD, discussed the phase 3 DeFi study exploring ovarian toxicity in female patients receiving nirogacestat for the treatment of desmoid tumors.

The application of remestemcel-L, a potential first-of-its-kind treatment for pediatric patients following stem cell transplants, has been resubmitted for FDA approval after addressing previous concerns.